Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043
Shanghai—Abbisko Therapeutics Co., Ltd.( HKEx code: 02256) today announces completion of dosing of the first patient in China in the Phase I clinical trial in advanced solid tumors for oral PD-L1 inhibitor ABSK043.
ABSK043 is a highly selective and potent small molecule PD-L1 inhibitor with excellent oral bioavailability, which may fill the gap of PD-1/PD-L1 antibodies in clinical application, such as high cost, poor blood-brain barrier penetration and immunogenicity, etc.
In preclinical studies, ABSK043 could effectively block PD-1/PD-L1 interaction and abolish the inhibition of T-cell induced by PD-L1. Its anti-tumor efficacy has been demonstrated in multiple mouse tumor models.
This trial (ABSK043-101) is the first clinical study of ABSK043 in China. Prior to this, first-in-human study of ABSK043 has been initiated in Australia in solid tumors. To date, multiple dosing cohorts have been completed in Australia with excellent PK/PD and safety profile observed.